Drug Approval | July 24, 2023
Lupin receives tentative USFDA’s approval for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets
This product would be manufactured at Lupin's Nagpur facility in India
This product would be manufactured at Lupin's Nagpur facility in India
Good momentum in commercial CDMO business
The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union
If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients
Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics
CMOs showed an increasing reluctance to take on debt in 2022
Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
Subscribe To Our Newsletter & Stay Updated
